AP2001002181A0 - Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses. - Google Patents

Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses.

Info

Publication number
AP2001002181A0
AP2001002181A0 APAP/P/2001/002181A AP2001002181A AP2001002181A0 AP 2001002181 A0 AP2001002181 A0 AP 2001002181A0 AP 2001002181 A AP2001002181 A AP 2001002181A AP 2001002181 A0 AP2001002181 A0 AP 2001002181A0
Authority
AP
ARIPO
Prior art keywords
virus
compounds
hepatitis
treatment
metabolites
Prior art date
Application number
APAP/P/2001/002181A
Other languages
English (en)
Inventor
Clarence Nathaniel Ahlem
James Martin Frincke
Patrick T Prendergast
Original Assignee
Hollis Eden Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hollis Eden Pharmaceuticals Inc filed Critical Hollis Eden Pharmaceuticals Inc
Publication of AP2001002181A0 publication Critical patent/AP2001002181A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
APAP/P/2001/002181A 1998-11-24 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses. AP2001002181A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10992498P 1998-11-24 1998-11-24
US12408799P 1999-03-11 1999-03-11
US12605699P 1999-03-23 1999-03-23
PCT/US1999/028082 WO2000032177A2 (en) 1998-11-24 1999-11-24 Use of 17-ketosteroids in the treatment of hepatitis c virus and other togavirus infections

Publications (1)

Publication Number Publication Date
AP2001002181A0 true AP2001002181A0 (en) 2001-05-24

Family

ID=27380740

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2001/002181A AP2001002181A0 (en) 1998-11-24 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses.

Country Status (14)

Country Link
EP (1) EP1133287A2 (id)
JP (1) JP2002531397A (id)
KR (1) KR20010101074A (id)
CN (1) CN1328463A (id)
AP (1) AP2001002181A0 (id)
AU (1) AU775614B2 (id)
BR (1) BR9915644A (id)
CA (1) CA2352205A1 (id)
HK (1) HK1042426A1 (id)
ID (1) ID29864A (id)
IL (2) IL142942A0 (id)
NZ (1) NZ511721A (id)
OA (1) OA11716A (id)
WO (1) WO2000032177A2 (id)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US6555523B1 (en) 1999-07-08 2003-04-29 Patrick T. Prendergast Use of cirsiliol and derivatives to treat infections
PT1955700E (pt) 1999-09-30 2011-05-04 Harbor Biosciences Inc Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
CN1665515A (zh) 2002-07-02 2005-09-07 科塞普特治疗公司 治疗与干扰素α治疗相关的精神病的方法
EP2298315A1 (en) * 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
ES2374117T3 (es) * 2007-11-15 2012-02-13 Madaus Gmbh Componente de silibinina para el tratamiento de la hepatitis.
CN102993148B (zh) * 2011-09-13 2015-12-09 复旦大学 槲皮素衍生物或其类似物及其应用
WO2013178782A1 (en) * 2012-05-30 2013-12-05 Universidad De Zaragoza Allosteric inhibitors of ns3 protease from hepatitis c virus
CN108003212A (zh) * 2017-12-24 2018-05-08 扬州工业职业技术学院 一种去氢表雄酮-6-葡萄糖苷衍生物及其作为抗丙型肝炎病毒药物的应用
CN110452280B (zh) * 2019-07-25 2020-11-17 中国人民解放军第二军医大学 一类四环三萜酸衍生物及其制备方法与应用
CA3193390A1 (en) * 2020-09-22 2022-03-31 Andrey Factor Nebulizer and nebulized anti-virals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
US5837269A (en) * 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
EP0901375A1 (en) * 1996-04-17 1999-03-17 Patrick Thomas Prendergast Dhea combination therapy
WO1998047516A1 (en) * 1997-04-17 1998-10-29 Prendergast Patrick T Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors

Also Published As

Publication number Publication date
IL142942A (en) 2006-08-20
EP1133287A2 (en) 2001-09-19
OA11716A (en) 2005-01-25
CN1328463A (zh) 2001-12-26
ID29864A (id) 2001-10-18
AU3105200A (en) 2000-06-19
IL142942A0 (en) 2002-04-21
WO2000032177A3 (en) 2001-03-22
BR9915644A (pt) 2001-08-07
AU775614B2 (en) 2004-08-05
WO2000032177A2 (en) 2000-06-08
JP2002531397A (ja) 2002-09-24
NZ511721A (en) 2004-07-30
HK1042426A1 (zh) 2002-08-16
KR20010101074A (ko) 2001-11-14
CA2352205A1 (en) 2000-06-08

Similar Documents

Publication Publication Date Title
AP1771A (en) 3'-Prodrugs of 2'-deoxy-?-L-nucleosides.
MXPA04012779A (es) Profarmacos de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae.
AU2002360592A8 (en) Inhibitors of hepatitis c virus
WO2004002999A3 (en) Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
PT1387681E (pt) Compostos antivirais
AP1727A (en) Methods and compositions for treating flaviviruses and pestiviruses.
TW200602350A (en) Methods and compositions for treating hepatitis C virus
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
ID27290A (id) Penggunaan senyawa 1,5-dideoksi-1,5-imino-d-glusitol tersubstitusi-n pada pengobatan infeksi virus hepatitis
AP2001002181A0 (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses.
MD940152A (ro) Compoziţie farmaceutică pentru tratarea infecţiilor şi bolilor, provocate de virusul hepatitei V (HBV)
SG165996A1 (en) Combination therapies with l-fmau for the treatment of hepatitis b virus infection
ATE348628T1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
AP2001002167A0 (en) Use of 17-ketosteroids for the treatment of toxoplasmosis and crytosporidiosis
UA31078A (uk) Інгібітор вірусу імунодефіциту людини ( даримід )
SG153666A1 (en) Treatment of hepatitis b virus infection with human monoclonal antibodies